Novo Nordisk is a protein-based, focused healthcare company where R&D is about being committed to not only engineering proteins into safe and effective therapies, but also developing new and improved delivery systems for people relying on our products.
Novo Nordisk is committed to engineering proteins into safe and effective therapies in a bioethical manner.
To this end, the company has developed position statements on bioethical issues in all key areas involving research on people and animals and the use of gene technology and stem cells. These position statements inform how we conduct R&D activities and are integrated into our standard operating procedures.
Novo Nordisk also takes an active role in advancing the field of bioethics in public forums. This is further reflected in the fact that we revisit our position statements periodically to ensure that they reflect new and relevant developments in the industry and changes in societal expectations.
Learn more about bioethics
Seize the opportunity to play a role in bringing innovation to the marketplace in a way that makes a real difference to both patients and society.
R&D career site
Insulin in a tablet – why is it so difficult?
Many companies have tried, and failed, to develop insulin in tablet form. So what makes Novo Nordisk think it can do any better?
Search through all clinical trial results from Novo Nordisk sponsored phase 1-4 trials and observational studies. Clinical trials are an important step in the research and development process to make new medications available.